Becton Dickinson’s Revenue by Region (2016-2022)

This statistic highlights Becton Dickinson’s Revenue by Region, across the United States and International, reported from Q1 2016 onwards.

Becton Dickinson’s Revenue by Region 

(All figures in USD billions, except percentages)

The total revenue is gradually increasing with each passing quarter. The incremental increase in revenue on a quarter-on-quarter basis, from $4.89 billion in Q3 2021 to $5.134 billion in Q4 2021 is 4.98%. Moreover, on yearly grounds, the total revenue increased from $4.784 billion in Q4 2020 to $5.134 billion in Q4 2021 marking a jump of 7.31% on a year-on-year basis. As shown, the highest total revenue of $5.134 billion is earned in the latest quarter–Q4 2021.(All figures in billions, except percentages)

The countries in which the Company has local revenue-generating operations have been grouped into the following geographic areas: the United States (including Puerto Rico) and International, which consists of EMEA, Greater Asia and other, which consists of Latin America.

International

The international operations of the company consist of EMEA (Europe, Middle East, and Africa); Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, and Australia and New Zealand); and Other, which consists of Latin America (including Mexico, Central America and the Caribbean).

COVID-19 diagnostic testing-related revenues in the Life Sciences segment’s Integrated Diagnostic Solutions unit and demand in the Medical segment’s Pharmaceutical Systems unit drove international revenue growth in 2021.

The profitability of overseas revenues has fluctuated more than the profitability of domestic revenues due to foreign economic conditions and exchange rate variations. Due to the economic environment, local commercial and economic policies, and political uncertainty, Becton Dickinson thinks its activities in some countries outside the United States pose a higher risk than its domestic business.

The international operations of the company contribute 45.40% to the company’s total revenue generated in Q4 2021. The revenue generated from this segment has been increasing quarterly. It grew by 14.71% on a year-on-year basis, from Q4 2020 where the revenue generated was $2.032 billion to $2.331 billion in Q4 2021. The contribution increased by a mere 0.65% on a quarter-on-quarter basis, from $2.316 billion in Q3 2021 to $2.331 billion in Q4 2021.

United States

Sales of COVID-19 diagnostic testing in the Life Sciences segment’s Integrated Diagnostic Solutions business drove revenue growth in the United States in 2021.

Strong revenue growth in the Medication Delivery Solutions unit of the Medical segment and the Surgery and Peripheral Intervention units of the Interventional segment in the fiscal year 2021 reflected positive comparisons to last year’s period results, which got impacted by COVID-19 pandemic-related declines, as well as growth attributable to core products. Strong demand in the Interventional segment’s Urology and Critical Care section contributed to revenue growth in the United States in 2021.

The United States contribute a major part to the company’s total revenue in Q4 2021, amounting to 54.60%. The revenue generated from this region grew by 1.85% on a year-on-year basis, from $2.758 billion in Q4 2020 to $2.803 billion in Q4 2021. The revenue generated by the United States fell by 6.46% from Q4 2020 to Q3 2021. However, it picked up pace and rose by 8.9% quarterly, from $2.574 billion in Q3 2021 to $2.803 billion in Q4 2021.

About the Company

Becton Dickinson is a global medical technology firm that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic items for hospitals, physicians, life science researchers, clinical laboratories, the pharmaceutical sector, and the general public.

The company offers customer solutions aimed at improving medication management and patient safety, as well as supporting infection prevention practices, equipping surgical and interventional procedures, improving drug delivery, assisting anesthesiology care, improving the diagnosis of infectious diseases and cancers, advancing cellular research and applications, and assisting diabetes management.

Did you like Becton Dickinson’s Revenue by Region statistic?

Access more such key performance indicator (KPI) data points, on thousands of US stocks, with Business Quant.

You can get started here.